In kidney disease–related bleeding disorders, which treatment is commonly used to shorten bleeding time by releasing stored von Willebrand factor and factor VIII?

In kidney disease–related bleeding disorders, which treatment is commonly used to shorten bleeding time by releasing stored von Willebrand factor and factor VIII?

• A. Cryoprecipitate
• B. Packed red blood cells
• C. Conjugated estrogen
• D. Desmopressin

Answer: (D)

Desmopressin works by triggering release of stored von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies, boosting platelet adhesion and reducing bleeding time in uremia. It acts on V2 receptors on the endothelium to raise circulating vWF and FVIII quickly, which helps correct the platelet dysfunction that often accompanies kidney disease. Cryoprecipitate would provide these factors directly but does not induce their release; packed red blood cells don’t address the coagulation defect, and estrogen isn’t used for uremic bleeding.

Desmopressin works by triggering release of stored von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies, boosting platelet adhesion and reducing bleeding time in uremia. It acts on V2 receptors on the endothelium to raise circulating vWF and FVIII quickly, which helps correct the platelet dysfunction that often accompanies kidney disease. Cryoprecipitate would provide these factors directly but does not induce their release; packed red blood cells don’t address the coagulation defect, and estrogen isn’t used for uremic bleeding.